-
Document de presse | 2024.10.23
Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research
PNAM2024: Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research through Strategic Memorandum of UnderstandingRio de Janeiro, October 23rd, 2024 – Key members of the Pasteur Network, including Fundação Oswaldo Cruz (Fiocruz), the Institut Pasteur de Dakar, the Institut Pasteur Korea, the Institut Pasteur, and the Institut Pasteur de Tunis, have signed a strategic...
-
News | 2016.01.19
A yellow fever vaccines production facility, grant maintained by AFD, in Dakar
The French Development Agency (AFD) grants 6.5 million euros to the Institut Pasteur in Dakar Foundation. The financing agreement has been signed, on January 19, 2016 in Dakar, for the construction and equipment of an over 3000 m2 new yellow fever vaccine production facility.The event has taken place in the presence of His Excellency Jean-Félix- Paganon, French Ambassador to Senegal; Laurence...
-
News | 2021.01.20
A vaccine candidate based on glycochemistry targets shigellosis: promising Phase 1 results
Diarrheal diseases are the world's second leading cause of death in children aged under 5 years, and of these, bacillary dysentery or shigellosis remains a major public health issue. This disease is most prevalent in African and South-East Asian countries, where it is endemic despite significant improvements in terms of access to drinking water and management of contaminated water. Consequently,...
-
Document de presse | 2021.11.18
Covid-19: Systematic review of the clinical and immunological efficacy of vaccines in immunocompromised people
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among...
-
Document de presse | 2021.07.01
Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria
On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has been identified as a likely adverse event following vaccination with the COVID-19 vaccine Vaxzevria. Researchers from the Mathematical Modelling of Infectious Diseases Unit at the Institut Pasteur used a mathematical model to assess its benefits and risks in...
-
News | 2019.09.27
Rabies: a shorter, cheaper vaccination schedule following a suspected rabid dog bite
A study by teams from the Institut Pasteur du Cambodge and the Institut Pasteur in Paris confirms the efficacy of the new post-exposure rabies vaccination schedule developed in the Institut Pasteur International Network and adopted by the World Health Organization (WHO). Since 2018, WHO has recommended post-exposure vaccination for rabies, immediately after a bite by a suspected rabid...
-
News | 2024.10.08
Can lymphoid organs-on-chip be used to evaluate the effectiveness of booster vaccines?
Researchers at the Institut Pasteur, a Carnot-labeled institute, have developed an innovative technology: "lymphoid organ-on-chip" devices that are capable of simulating the human immune system’s response to booster vaccines. This breakthrough could provide a versatile preclinical system to evaluate vaccine candidates in the face of rapidly evolving pandemics such as that caused by the SARS-CoV-2...
-
News | 2017.10.20
Malaria: Plasmodium falciparum protein MSP4 is a potential target for a vaccine
According to WHO estimates, in 2015, there were 212 million cases of malaria and 429,000 deaths worldwide. Sub-Saharan Africa alone accounts for 90% of cases and 92% of deaths. In this region, the parasite Plasmodium falciparum, responsible for the majority of deaths, is the most common/frequent. Since 2010, integrated control measures (insecticide-treated mosquito nets, insecticide sprays, etc...
-
Article | 2020.06.16
Generation of animal models sensitive to SARS-CoV-2 to test vaccines or drugs
Aim: Rapid development of animal models is of utmost importance to test the efficacy of vaccines and drug against COVID-19. The aim of this research project is to propose models whose cells express the human ACE2 proteins (huACE2) so that they are sensitive to SARS-CoV-2. The ACE2 protein is the gateway for the virus to enter cells. Researchers are proposing to use adenoviruses and...
-
Document de presse | 2004.02.19
Rift Valley Fever: New Therapeutic Targets and a Candidate Vaccine in Trials
Research teams from INSERM and the Institut Pasteur have just discovered the virulence mechanism of the Rift Valley Fever virus. This virus, often fatal in humans, regularly decimates herds of livestock in Africa. Understanding the interactions between the host and this virus should make it possible to identify new therapeutic targets against Rift Valley Fever. This research, published in the...